Key Drivers
- Strong margins
- Solid cash flow
- Leverage pressure
AIAI Summary
CNMD is now a margin-and-execution story rather than a top-line growth story: if it can sustain ~6% organic growth ex-GI exits and keep gross/operating margins improving, the stock can work, but with 27.9x earnings, leverage, and only modest reported revenue growth, any execution slip leaves little valuation cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid cash flow
- •Leverage pressure
CNMD remains fundamentally solid, with strong margins and cash generation offset by meaningful leverage, softer liquidity, and a fairly full valuation.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Support holding
- •Overbought stretch
CNMD is in a constructive uptrend, holding $49.10–$49.30 support after a fast rise toward $51.86, but overhead resistance suggests near-term consolidation or pullback risk before a breakout.
Rapid climb from $43.20 to $51.86 signals short-term overbought risk
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Guidance Raise
- •FDA Expansion
CNMD reported a Q2 2026 beat with stronger organic growth, margin expansion and raised full-year guidance, while expanded AirSeal FDA clearance and rising institutional ownership reinforce a positive robotics-surgery outlook.
The latest results and product wins should support sentiment and may drive a modestly positive re-rating if execution stays strong
Similar Companies in Healthcare
Other companies in the same sector with AI ratings